A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia.

• প্রধান লেখক: Ermias Diro (লেখক), Severine Blesson (লেখক), Tansy Edwards (লেখক), Koert Ritmeijer (লেখক), Helina Fikre (লেখক), Henok Admassu (লেখক), Aderajew Kibret (লেখক), Sally J Ellis (লেখক), Clelia Bardonneau (লেখক), Eduard E Zijlstra (লেখক), Peninah Soipei (লেখক), Brian Mutinda (লেখক), Raymond Omollo (লেখক), Robert Kimutai (লেখক), Gabriel Omwalo (লেখক), Monique Wasunna (লেখক), Fentahun Tadesse (লেখক), Fabiana Alves (লেখক), Nathalie Strub-Wourgaft (লেখক), Asrat Hailu (লেখক), Neal Alexander (লেখক), Jorge Alvar (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Public Library of Science (PLoS), 2019-01-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

<h4>Background</h4>Visceral leishmaniasis (VL) in human immunodeficiency virus (HIV) co-infected patients requires special case management. AmBisome monotherapy at 40 mg/kg is recommended by the World Health Organization. The objective of the study was to assess if a combination of a low...